Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 12/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.63 |
| ▸ | NAMPT | P43490 | 2/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.46 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.46 |
| ▸ | ITGAV | P06756 | 1/20 | 0.46 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.46 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10160238 | 0.89 | ROCK2 (0.74) | ROCK2CYP3A4CYP2C19 | |
| SCHEMBL6661030 | 0.83 | GLS (0.52) | ROCK2CYP3A4NAMPTHDAC1 | |
| SCHEMBL14135172 | 0.83 | ROCK2 (0.71) | ROCK2CYP3A4CYP2C19 | |
| SCHEMBL15888437 | 0.82 | ROCK2 (0.70) | ROCK2CYP3A4CYP2C19MAPT | |
| SCHEMBL306324 | 0.81 | ROCK2 (0.78) | ROCK2CYP3A4CYP2C19MAPT | |
| SCHEMBL307838 | 0.81 | ROCK2 (0.81) | ROCK2CYP3A4CYP2C19 | |
| SCHEMBL307464 | 0.80 | ROCK2 (0.76) | ROCK2CYP3A4CYP2C19NAMPTHDAC1 | |
| SCHEMBL307780 | 0.80 | ROCK2 (0.72) | ROCK2CYP3A4CYP2C19TDP1 | |
| SCHEMBL307583 | 0.80 | ROCK2 (0.80) | ROCK2CYP3A4CYP2C19NAMPT | |
| SCHEMBL307681 | 0.80 | ROCK2 (0.76) | ROCK2CYP3A4CYP2C19MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2114869-B1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2014-07-23 | — | — | EP | disclosed |
| US-8093266-B2 | Rho kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-10 | — | — | US | disclosed |
| US-20100041645-A1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041645-A1 | RHO KINASE INHIBITORS | CIT, ROCK1, RHOT2 | ROCK2 4/4885CYP3A4 2048/4885CYP2C19 1265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.